Skip to main content
PBLS $28.68 +1.52%
PBLS logo
PBLS · Parabilis Medicines, Inc.
Track PBLS — free
$28.68 +0.43 (+1.52%)
Market Cap
$3.54B
Shares
125.26M
Volume · Nov 18 203.63K Avg daily vol (3M) 944.98K
All webcasts

Earnings call · FY2026 Q3

Parabilis Medicines, Inc. (PBLS) Q3 2026 Earnings Call

Concluded Nov 12, 2026
Nov 12, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $2.11M
Diluted EPS -$0.36
Net income -$44.49M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 12, 2026
Parabilis Medicines reported a 72.2% objective response rate at the 32-week landmark among evaluable desmoid-tumor patients receiving a starting dose of ≥450 mg; $1.1 billion in cash, cash equivalents and marketable securities is expected to fund operations into 2030.
10-Q report · filed Nov 12, 2026
Net loss widened to $44.5 million for the three months ended September 30, 2026, from $33.5 million a year earlier. Research and development expense rose to $45.6 million, mainly from higher external costs for zolucatetide. Cash, cash equivalents and marketable securities totaled $1,072.9 million at September 30, 2026, which the company expects to fund operations into 2030.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document